MarketCapExport financials
Epizyme (EPZM)
The export includes the complete available history of financial statements and ratios. Numbers are provided in full, without million or billion abbreviations, in their original reporting units.
CSV downloads as a ZIP archive with one file for each report and frequency.
Facebook
X
Telegram
Epizyme Income Statement 2021-2010 | EPZM
Brief overview of profit and loss at Epizyme
The overview follows changes across a five-year period. Revenue reported by Epizyme was $8 million at the beginning of the period and $37.4 million at the end. The cumulative result was +367.4%, corresponding to roughly 36.1% per year. The company expanded its revenue base at a high speed.
Over the period, EBITDA shifted from −110 million dollars to −233 million dollars, a change of −111.1%. EBITDA lagged revenue, showing weaker operating momentum. Comparing the endpoints gives EBITDA margins of −1376.8% and −621.9%. The business generated more EBITDA from each unit of revenue.
Comparing the endpoints shows a move from −110 million dollars to −251 million dollars. The negative result deepened, showing weaker final efficiency.
The five-year change in capitalization reached −79%: from $600 million to $126 million. The market has not yet confirmed the improvement in fundamentals.
Overall conclusion
Signs of deterioration dominate the five-year picture. The strongest signals are higher operating efficiency and sales growth. The most visible risks are a narrow EBITDA buffer, lower investor confidence and lower net income. Further direction will depend on top-line growth, operating profitability, and net income.
Annual Income Statement Epizyme
| 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Market Cap |
126 M | 1.11 B | 1.88 B | 734 M | 993 M | 600 M | 362 M | 632 M | 518 M | - | - | - |
Shares |
103 M | 101 M | 89.9 M | 71.9 M | 61.5 M | 57.1 M | 39.8 M | 33 M | 17 M | 1.64 M | 1.43 M | - |
Historical Prices |
1.23 | 10.9 | 20.9 | 10.2 | 16.1 | 10.5 | 9.09 | 19.1 | 30.4 | - | - | - |
Net Income |
-251 M | -232 M | -170 M | -124 M | -134 M | -110 M | -132 M | -55 M | -3.48 M | -702 K | -21 M | - |
Revenue |
37.4 M | 15.8 M | 23.8 M | 21.7 M | 10 M | 8.01 M | 2.56 M | 41.4 M | 68.5 M | 45.2 M | 6.94 M | - |
Cost of Revenue |
10.5 M | 5.07 M | - | - | - | - | - | - | - | - | - | - |
Gross Profit |
- | 10.7 M | - | - | - | - | - | - | - | - | - | - |
Operating Income |
-238 M | -225 M | -177 M | -128 M | -137 M | -112 M | -133 M | -55 M | -3.13 M | -768 K | -21 M | - |
Interest Expense |
-22.4 M | -3.97 M | 1.15 M | -25 K | 32 K | 83 K | 79 K | 59 K | -81 K | -78 K | -23 K | - |
EBITDA |
-233 M | -221 M | -176 M | -127 M | -135 M | -110 M | -131 M | -54.3 M | -2.42 M | 79 K | -20.5 M | - |
Operating Expenses |
- | 236 M | 201 M | 150 M | 147 M | 120 M | 135 M | 96.5 M | 71.6 M | - | - | - |
General and Administrative Expenses |
134 M | 125 M | 23.5 M | 12.2 M | 37.2 M | 28.4 M | 23.9 M | 20.9 M | 14 M | 7.51 M | 5 M | - |
Annual performance
Select metrics to display
All numbers in USD currency
Quarterly Income Statement Epizyme
| 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Shares |
- | - | 167 K | 144 K | 106 M | 103 M | 102 M | 102 M | 102 M | 102 M | 101 M | 99.6 M | 95.1 M | 91 M | 90.9 M | 82.4 M | 79 M | 69.5 M | 69.5 M | 69.4 M | 69.3 M | 59.9 M | 58.4 M | 58.2 M | 58 M | 58 M | 57.4 M | 55.1 M | 41.7 M | 41.5 M | 41.1 M | 35 M | 34.3 M | 33.7 M | 33.2 M | 31 M | 28.4 M | 28.4 M | 9.15 M | 1.79 M | 1.67 M | 1.65 M | 1.64 M | 1.62 M | - | - | - | - |
Net Income |
- | - | -35.7 M | -55.5 M | - | -65.8 M | -64.4 M | -70.3 M | -66.2 M | -56.1 M | -58.5 M | -50.9 M | -56.4 M | -36.1 M | -48.5 M | -29.3 M | -22.9 M | -37.5 M | -29.1 M | -34.1 M | -36.2 M | -37.6 M | -28 M | -32.5 M | -35 M | -24.3 M | -28 M | -22.9 M | -22.2 M | -23.1 M | -25.8 M | -61.3 M | -15 M | -19.7 M | -13.4 M | -6.88 M | 15.9 M | -9.7 M | -2.21 M | -7.5 M | -4.54 M | 4.45 M | 4.86 M | -5.47 M | - | - | - | - |
Revenue |
- | - | 27.5 M | 8.7 M | - | 5.2 M | 13 M | 7.63 M | 8.38 M | 3.57 M | 2.47 M | 1.35 M | 4.29 M | 5.72 M | 5.9 M | 7.89 M | 9.7 M | 12 M | 12 M | - | - | 10 M | 10 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Cost of Revenue |
- | - | 5.17 M | 2.64 M | - | 2 M | 2.49 M | 2.85 M | 1.82 M | 1.61 M | 1.02 M | 614 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Operating Income |
- | - | -29.8 M | -50.9 M | - | -64.1 M | -58.2 M | -64.3 M | -62.1 M | -54.4 M | -57.6 M | -51.4 M | -57.5 M | -38 M | -50.7 M | -31 M | -24.3 M | -38.6 M | -30.3 M | -35 M | -37.4 M | -38.1 M | -28.5 M | -33 M | -35.5 M | -24.8 M | -28.4 M | -23.1 M | -22.3 M | -23.1 M | -25.8 M | -61.4 M | -15.1 M | -19.7 M | -13.3 M | -6.91 M | 16.3 M | -9.73 M | -2.18 M | -7.48 M | -4.54 M | 4.44 M | 4.8 M | -5.48 M | - | - | - | - |
Interest Expense |
- | - | -5.39 M | -5.48 M | - | -5.64 M | -5.58 M | -5.48 M | -3.97 M | -1.72 M | -885 K | -48 K | 1.15 M | -15 K | -13 K | -6 K | - | -6 K | -11 K | 18 K | - | -32 K | 10 K | 4 K | - | 21 K | - | - | - | - | - | 20 K | - | 17 K | 12 K | 12 K | - | 3 K | -50 K | -39 K | - | -39 K | - | - | - | - | - | - |
EBITDA |
- | - | -27.2 M | -49.6 M | - | -60.2 M | -55.6 M | -63.1 M | -62.1 M | -51.7 M | -56.2 M | -50.8 M | -57.5 M | -37.3 M | -50.3 M | -30.8 M | -24.3 M | -37.8 M | -29.7 M | -34.6 M | -37.4 M | -36.8 M | -27.6 M | -32.6 M | -35.5 M | -23.6 M | -27.6 M | -22.7 M | -22.3 M | -22 M | -25.1 M | -61.1 M | -15.1 M | -19.2 M | -12.9 M | -6.74 M | 16.3 M | -9.19 M | -1.81 M | -7.3 M | -4.54 M | 4.88 M | 5.1 M | -5.48 M | - | - | - | - |
General and Administrative Expenses |
- | - | 24.1 M | 27.2 M | - | 32.8 M | 33.9 M | 36.4 M | 35 M | 30.6 M | 32.7 M | 26.9 M | 23.5 M | 17.1 M | 15.7 M | 12 M | 12.2 M | 11.5 M | 10.9 M | 9.36 M | 8.43 M | 9.31 M | 11.2 M | 8.27 M | 7.58 M | 7.52 M | 7.42 M | 5.85 M | 6.02 M | 6.68 M | 5.97 M | 5.24 M | 4.94 M | 5.67 M | 5.31 M | 4.96 M | 4.38 M | 3.59 M | 3.08 M | 3 M | 2.33 M | 1.63 M | 1.64 M | 1.91 M | - | - | - | - |
Quarterly performance
Select metrics to display
All numbers in USD currency
The income statement is one of the three key financial reports of a company Epizyme (alongside the balance sheet and the cash flow statement). It shows how the company makes money and what its expenses are:
- How much revenue the company earned
- How much it spent on production, personnel, marketing, taxes, etc.
- What profit remained in the end
Analyzing the income statement helps an investor understand whether the business generates stable and growing profits, how effectively the company controls its expenses, and whether it is capable of generating income in the future. Additionally, this analysis shows how the company copes with crises and economic cycles, and allows assessing the potential for stock price growth and dividend payments.
Features- The income statement may include both recurring and one-time items (for example, profit from the sale of assets). It is necessary to separate core metrics from one-off events for accurate analysis.
- Companies often publish interim reports (e.g., quarterly), which allows for more timely tracking of trends.
- A combined analysis of the income statement with the balance sheet and cash flow statement provides a comprehensive view of the company’s financial health.
Russia
USA
Canada
Niderland
Israel
Schweiz
Australia
Britain
